Related Experiment Video

Updated: Aug 31, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin

Ireneusz Majsterek1, Artur Slupianek, Janusz Blasiak

  • 1Department of Molecular Genetics University of Lodz, Poland. imajst@yahoo.com

Anti-Cancer Drugs
|September 23, 2003
PubMed

Insights

TEL-related fusion tyrosine kinases (FTKs) enhance DNA repair, contributing to leukemia cell resistance against idarubicin chemotherapy. This suggests FTKs play a key role in drug resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Fusion tyrosine kinases (FTKs) are implicated in drug resistance during leukemogenesis.
  • Previous research suggests DNA repair stimulation as a resistance mechanism in FTK+ cells.

Purpose of the Study:

  • To investigate the role of TEL family fusion oncoproteins in cellular response to idarubicin.
  • To determine if TEL-related FTKs influence DNA repair following idarubicin treatment.

Main Methods:

  • Utilized murine pro-B lymphoid cell line BaF3 and its TEL/ABL, TEL/JAK2, and TEL/PDGFbetaR-transformed clones.
  • Assessed idarubicin resistance and DNA damage using the alkaline Comet assay.
  • Monitored DNA damage repair kinetics in transformed versus non-transformed cells.

Main Results:

  • Transformed cells demonstrated resistance to idarubicin (0.01-1 microM) compared to control cells.
  • Idarubicin induced DNA damage in both cell types, but transformed cells repaired it 2x faster (60 min vs. 120 min).

Conclusions:

  • TEL-related FTKs appear to accelerate the repair of idarubicin-induced DNA damage.
  • This enhanced DNA repair mechanism is likely significant for leukemic cell resistance to idarubicin.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.